The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Bicycle modifications can potentially improve genitourinary outcomes after cycling. For example, in our cohort, cyclists who stood more than 20% of the time while cycling and adjusted the handlebar to ...

Key Takeaways Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Key Takeaways Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T ...

For almost my entire career, I have recognized the importance of government funding for cancer research. These trials have provided guidance and options for the treatment of patients with cancer that ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

The AUA released its guidelines in 2018, making a strong recommendation that clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate ...

On July 10, 2024, the Centers for Medicare & Medicaid Services (CMS) released the Calendar Year (CY) 2025 Medicare Physician Fee Schedule Proposed Rule. It outlines CMS’ proposed updates for payments ...

The combination of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) with docetaxel improved outcomes in patients metastatic hormone-sensitive prostate cancer (mHSPC) without an ...